# US 2020/0390787 A1 · Methods and compositions of bile acids and salts for reduction of fat

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390787 A1
- Document ID: US20200390787A1
- Status: Published application
- Kind: A1
- Application number: 16/908,164
- Filed: 2020-06-22
- Published: 2020-12-17
- Earliest claimed: 2014-06-27
- Assignees: Medytox Inc.
- Applicants: Medytox Inc.
- Inventors: Hyun Ho JUNG; Gi Hyeok YANG; Junho LEE; Sujin CHO
- Web page: https://patentgrep.com/patent/US20200390787A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 8/63: Steroids; Derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 23/00: Anaesthetics
- A61P 25/20: Hypnotics; Sedatives
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/06: for countering cellulitis
- A61K 2800/74: Biological properties of particular ingredients
- A61K 2800/88: Two- or multipart kits
- A61K 2800/91: Injection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A formulation comprising cholate, chenodeoxycholate, glycine or taurine conjugate of cholate, glycine or taurine conjugate of chenodeoxycholate, or any mixture thereof, and at least one pharmaceutically acceptable carrier, wherein the formulation has a pH of less than 9, and the formulation is an aqueous solution and is free of precipitate or gel form at 25° C.

### Claim 24 (depends on 23)

The formulation of claim 23, wherein the formulation has a pH of about 8 or less.

### Claim 25 (depends on 24)

The formulation of claim 24, wherein the formulation has a pH of about 7.5 or less.

### Claim 26 (depends on 24)

The formulation of claim 24, wherein the formulation has a pH of about 7 to about 8.

### Claim 27 (depends on 26)

The formulation of claim 26, wherein the formulation has a pH of about 7 to about 7.5.

### Claim 28 (depends on 26)

The formulation of claim 26, wherein the formulation has a pH of about 7.5 to about 8.

### Claim 29 (depends on 23)

The formulation of claim 23, wherein the formulation has cholate or chenodeoxycholate from about 0.5% by weight to about 4.0% by weight.

### Claim 30 (depends on 29)

The formulation of claim 29, wherein the formulation has cholate or chenodeoxycholate from about 0.5% by weight to about 2.0% by weight.

### Claim 31 (depends on 23)

The formulation of claim 23, comprising cholate, or glycine or taurine conjugate thereof.

### Claim 32 (depends on 23)

The formulation of claim 23, comprising chenodeoxycholate, or glycine or taurine conjugate thereof.

### Claim 33 (depends on 23)

The formulation of claim 23, comprising cholate or chenodeoxycholate.

### Claim 34 (depends on 33)

The formulation of claim 33, comprising cholate.

### Claim 35 (depends on 33)

The formulation of claim 33, comprising chenodeoxycholate.

### Claim 36 (depends on 23)

The formulation of claim 23, wherein at least one pharmaceutically acceptable carrier is selected from the group consisting of an excipient; a surface active agent; a dispersing agent; an inert diluent; a granulating and disintegrating agent; a binding agent; a lubricating agent; a sweetening agent; a flavoring agent; a coloring agent; a preservative; an aqueous vehicle and solvent; an oily vehicle and solvent; a suspending agent; a wetting agent; an emulsifying agent; a demulcent; a buffer; a salt; a thickening agent; a filler; an antioxidant; an antibiotic; an antifungal agent; and a stabilizing agent.

### Claim 37 (depends on 36)

The formulation of claim 36, wherein the formulation comprises a buffer.

### Claim 38 (depends on 36)

The formulation of claim 36, wherein the formulation comprises an emulsifying agent.

### Claim 39 (depends on 23)

The formulation of claim 23, further comprising a therapeutic agent selected from the group consisting of an anti-microbial agent, a vasoconstrictor, an anti-thrombotic agent, an anti-coagulation agent, a suds-depressant, an anti-inflammatory agent, an analgesic, an anti-dispersion agent, a penetration enhancer, a steroid, a tranquilizer, a muscle relaxant, an anti-diarrhea agent, and any combination thereof.

### Claim 40 (depends on 23)

The formulation of claim 23, wherein the formulation is an injectable formulation.

### Claim 41 (depends on 23)

The formulation of claim 23, wherein the formulation is a lipolysis injection formulation.

### Claim 42 (depends on 23)

The formulation of claim 23, wherein the formulation is suitable for subcutaneous injection.
